Fierce Pharma reports FDA approval of MYCAPSSA (oral octreotide) as the first oral therapy for acromegaly maintenance, following a 2016 complete response and a patient-advocacy-driven refile. The piece details launch pricing at $5,152 per 28-day course and Chiasma's switch to a subscription model.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.